Schaper Benz & Wise Investment Counsel Inc. WI grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 216,722 shares of the biopharmaceutical company’s stock after acquiring an additional 4,644 shares during the quarter. Schaper Benz & Wise Investment Counsel Inc. WI’s holdings in Pfizer were worth $7,787,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also modified their holdings of the company. Evolution Wealth Advisors LLC bought a new stake in shares of Pfizer during the 2nd quarter worth approximately $34,000. IMA Wealth Inc. lifted its stake in Pfizer by 144.5% during the 2nd quarter. IMA Wealth Inc. now owns 807 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 477 shares in the last quarter. 1 North Wealth Services LLC bought a new position in Pfizer during the 3rd quarter valued at $29,000. B & T Capital Management DBA Alpha Capital Management bought a new position in Pfizer during the 3rd quarter valued at $36,000. Finally, Financial Gravity Wealth Inc. lifted its stake in Pfizer by 33.2% during the 2nd quarter. Financial Gravity Wealth Inc. now owns 1,031 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 257 shares in the last quarter. Hedge funds and other institutional investors own 71.52% of the company’s stock.
In other news, major shareholder Pfizer Inc acquired 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 17th. The stock was bought at an average price of $18.00 per share, with a total value of $900,000.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Scott Gottlieb acquired 3,000 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The stock was purchased at an average cost of $34.72 per share, with a total value of $104,160.00. Following the acquisition, the director now owns 3,000 shares in the company, valued at approximately $104,160. The disclosure for this purchase can be found here. Company insiders own 0.09% of the company’s stock.
Several brokerages have weighed in on PFE. JPMorgan Chase & Co. restated a “neutral” rating on shares of Pfizer in a research note on Tuesday, October 29th. Bank of America began coverage on Pfizer in a research note on Wednesday, October 16th. They set a “neutral” rating and a $37.00 price objective on the stock. Credit Suisse Group restated a “hold” rating and set a $41.30 price objective on shares of Pfizer in a research note on Wednesday. Morgan Stanley dropped their price objective on Pfizer from $40.00 to $38.00 and set an “equal weight” rating on the stock in a research note on Tuesday, August 27th. Finally, Zacks Investment Research upgraded Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price objective on the stock in a research note on Tuesday, October 1st. Nine investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $44.02.
Shares of Pfizer stock traded up $0.14 during trading hours on Friday, hitting $37.05. 25,262,666 shares of the company’s stock traded hands, compared to its average volume of 23,366,957. Pfizer Inc. has a 12-month low of $33.97 and a 12-month high of $46.47. The stock has a market capitalization of $207.30 billion, a price-to-earnings ratio of 12.35, a PEG ratio of 2.11 and a beta of 0.67. The company has a fifty day simple moving average of $36.61 and a 200-day simple moving average of $39.27. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.47 and a quick ratio of 1.21.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.13. Pfizer had a return on equity of 28.61% and a net margin of 30.57%. The firm had revenue of $12.68 billion during the quarter, compared to analyst estimates of $12.37 billion. During the same period last year, the firm posted $0.78 EPS. The business’s revenue was down 4.6% compared to the same quarter last year. On average, analysts forecast that Pfizer Inc. will post 2.96 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a dividend of $0.36 per share. This represents a $1.44 annualized dividend and a dividend yield of 3.89%. The ex-dividend date of this dividend is Thursday, November 7th. Pfizer’s dividend payout ratio is presently 48.00%.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Recommended Story: Day Trading – Risk Worth the Reward?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.